Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.

Inclusion Criteria:

• Renal findings: Hypertensive patients with renal dysfunction and stable renal condition at least 4 weeks before screening visit.
• Satisfy office msSBP ≥140 mmHg and <180 mmHg at baseline.

Exclusion Criteria:

• Patients show msDBP ≥110 mmHg and/or msSBP ≥180 mmHg.
• History of angioedema, drug-related or otherwise, as reported by the patient.
• Any other following renal disorder:
• Patients show eGFR < 15mL/min/1.73m^2
• Patients on dialysis
• Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.

Other protocol-defined inclusion/exclusion criteria may apply.